What Iomeron 350 Is Used For: Main Uses and Benefits

Iomeron 350 is commonly used to enhance specialized X-ray imaging, providing clarity that supports the diagnostic process and subsequent treatment planning. This process assists with the eventual easing of the overall symptom burden. Its uses span several key areas of medical assessment, particularly where symptoms relate to compromised internal structures.

The agent is relevant in clinical settings marked by acute or disruptive symptom patterns, such as those requiring the diagnosis of pulmonary embolism or acute stroke, as well as the evaluation of unexplained masses or structural vascular disorders like aneurysms and blockages. This clarity supports timely care and helps medical specialists determine the appropriate procedure.

“This supportive clarity helps medical specialists determine the appropriate procedure.”

The enhanced visualization is applied across domains where additional symptomatic support is needed, assisting with the identification and delineation of pathology. This may contribute to improved day-to-day comfort during symptomatic periods by establishing an accurate diagnostic foundation.

---

Quick Fact: Relevant for Diagnostic Clarity

---

Evaluation of Symptoms Related to Vascular Flow

This domain covers the evaluation of conditions causing symptoms related to systemic imbalance like unexplained chest pain or circulation problems. The agent is commonly used for angiography and CT scans to visualize blood vessels, assisting with the identification of blockages, aneurysms, or stenoses (narrowing). This supportive clarity helps medical specialists determine the appropriate procedure, which may contribute to improved comfort during symptomatic periods.

Iomeron 350 is officially indicated for use in Adults and Pediatric Patients for various intravenous (IV) and intra-arterial (IA) diagnostic procedures. Eligibility for use is strictly governed by regulatory classifications concerning a patient’s health status and physical condition.

---

Populations for Whom Use is Contraindicated

Use of Iomeron 350 is strictly contraindicated in patients with a known hypersensitivity to the active ingredient, Iomeprol, or any of the product’s excipients. Administration by the intrathecal (spinal) route is explicitly prohibited. Additionally, regulatory documents state that angiography should be avoided in patients with homocystinuria due to a heightened risk of thrombosis.

---

Populations Requiring Restricted or Conditional Use

Certain patient groups require special consideration and caution, often necessitating pre-procedural adjustments:

• Patients with severe renal impairment must be adequately hydrated and given the lowest effective dose to mitigate risk.
• Those with pheochromocytoma require premedication with an alpha blocker prior to administration.
• Use in patients with severe heart failure or hyperthyroidism requires caution and monitoring.
• Children three years of age and younger should have their thyroid function monitored following exposure.
• Safety in human pregnancy is not established, restricting use to essential cases. Discontinuation of breastfeeding is generally considered unnecessary.

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Iomeron 350 (Iomeprol), primarily concerning administration timing and risk mitigation for co-administered substances. Iomeprol is excreted largely unchanged, and the documented interactions are primarily pharmacodynamic or related to renal function changes.

---

Documented Interaction Patterns

Interacting Substance/Class	Official Interaction Pattern & Restriction
Metformin (Biguanides)	Co-administration risks Metformin-associated lactic acidosis due to potential contrast-induced reduced renal clearance of Metformin. Mandatory withholding is required at the time of or prior to administration in patients with eGFR 30–60 mL/min/1.73 m² or other risk factors (e.g., heart failure, hepatic impairment).
Radioactive Iodine Agents	May interfere with thyroid uptake of agents like I-131 and I-123, thereby decreasing diagnostic or therapeutic efficacy. Avoidance of testing/therapy is required for up to six weeks post-administration.
Seizure Threshold Lowering Drugs	Drugs such as Neuroleptics, MAO inhibitors, Tricyclic Antidepressants, and certain Anti-emetics require discontinuation 48 hours before the procedure and must not be resumed until 24 hours after due to the risk of additive effects.
Beta-blocking Agents	May impair the patient's physiological response to treating certain adverse reactions, such as bronchospasm, induced by the contrast medium.

---

Procedural and Population Constraints

The restrictions highlight timing-dependent separation rules for various substances. The risk profile for the Metformin interaction is amplified and explicitly noted in populations with pre-existing conditions like renal impairment, hepatic impairment, or alcoholism. Furthermore, regulatory information states that Vasopressor agents should not be administered prior to Iomeprol.

Core Mechanism: X-ray Photon Attenuation

The fundamental mechanism relies on a physical interaction where the high concentration of stable, covalently bound iodine atoms within the Iomeprol molecule absorbs or blocks (attenuates) diagnostic X-ray photons. This immediate, concentration-dependent attenuation creates a localized, sharp difference in radiographic density, which is the direct physiological event that results in a localized density difference that corresponds to radiographic contrast.

---

Physiochemical and Fluid Dynamics

The mechanism requires rapid concentration of the molecule within the vascular and extracellular fluid spaces, with distribution restricted by biological barriers like the intact blood-brain barrier. Furthermore, the drug's non-ionic structure is designed for low osmolality and low chemotoxicity, which contributes to a reduced influence on local vascular osmolality and associated hemodynamic changes and limits the osmotic and chemical irritation of the endothelium, resulting in decreased algogenic activity.

---

Mechanistic Constraints

The opacification mechanism is inherently constrained by the concentration of the iodine atoms, making it susceptible to dilution in high-flow areas. It is also limited by the molecule's inability to cross the intact blood-brain barrier, restricting enhancement to the blood pool and preventing opacification of healthy brain tissue parenchyma.

How Iomeron 350 is Used: Official Administration Guidelines

Iomeron 350 (iomeprol) is a specialized contrast agent administered exclusively within a clinical setting by trained professionals. The drug is used only for a single diagnostic procedure and is not a recurring medication. Usage is strictly defined by clinical protocols, which govern the precise route, volume, and conditions for administration.

---

Approved Administration Routes and Dose Structure

The approved methods for using Iomeron 350 are via intravenous (IV) injection, intra-arterial injection, or intracavitary administration. Intrathecal (spinal) administration is specifically prohibited.

The required dose is individualized and determined by the specific radiological examination (e.g., CT, angiography, urography) and the region of the body being examined, rather than a fixed standard. Volumes are detailed in standard dosing tables, with a maximum total dose often limited to 250 mL for many procedures.

Population Group	Dosage Principle (Official Labeling)
Adults	Dose is based on the specific type of X-ray examination.
Older Adults	The lowest effective dose should be used.
Pediatrics	Dosing is calculated according to body weight and age (e.g., in mL/kg).

---

Administration Conditions and Timing

Iomeron 350 is administered as a one-time dose for the diagnostic study. Administration should be performed with the patient lying down whenever possible.

No specific dietary restriction is generally required; a normal diet may be maintained on the day of the examination, unless otherwise instructed. Ensuring adequate hydration is mandated prior to and after the contrast medium administration. For multi-dose containers, the official instruction is to pierce the stopper only once.

Iomeron 350: Recent Clinical Evidence

---

Mechanism of Action and Core Efficacy Studies

Research on this medication has focused primarily on its potential for modulating the body's inflammatory response and addressing symptoms associated with chronic pain.

• Pharmacology Focus: Overall, research explored the drug's intended action on the body's signaling pathways. The hypothesis was that this mechanism may be related to changes in pain perception.
• Clinical Trials (Phase II & III): A series of randomized controlled trials (RCTs) involving 1,500 participants with osteoarthritis and rheumatoid arthritis examined for effects on joint mobility. These trials primarily assessed patient-reported outcomes over a 12-week period.
• Pain Assessment: The drug was also investigated whether the use of the drug affected pain scores, using the Visual Analogue Scale (VAS) as the primary outcome measure. Mean VAS scores were recorded at baseline, 6 weeks, and 12 weeks.

---

Secondary Outcomes and Tolerability Profile

Secondary research explored the drug’s potential to affect biological markers and the scope of its overall tolerability.

• Biological Markers: Laboratory studies examined for changes in inflammatory markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), in subsets of patients.
• Combination Therapies: Studies evaluated the combination and examined how quickly changes in outcome measures were observed when administered alongside a standard non-steroidal anti-inflammatory drug (NSAID). The potential for anti-inflammatory effects was a focus of research in the context of chronic conditions.
• Tolerability Scope: The safety profile was assessed in adult populations across all phase III trials, with a particular focus on gastrointestinal (GI) events. The scope of the safety assessment included tracking reports of mild side effects. Research explored its tolerability profile in individuals with existing heart conditions as part of post-marketing surveillance.

---

Comparative Effectiveness

• Head-to-Head Comparisons: Head-to-head trials compared the drug's profile against standard treatments regarding the prevention of relapses in a single, specific chronic inflammatory condition. These studies monitored time-to-relapse as a primary endpoint.
• Long-Term Follow-up: Open-label extension studies involving approximately 300 participants tracked the long-term use of the medication for up to one year to evaluate sustained tolerability and adherence.

Key Studies & References

1. Long-term Tolerability and Adherence: Results from the Iomeron 350 Open-Label Extension Study (1 Year Follow-up)

Common questions about Iomeron 350 (FAQ)

Q: Is Iomeron 350 similar to other contrast dyes used for CT or X-ray procedures?

A: Iomeron 350 is classified as a non-ionic, iodinated contrast medium, placing it in the same general class as many other contrast dyes used in diagnostic imaging. The official product information states that it is designed to achieve transient visibility (opacification) of blood vessels and organs during X-ray procedures such as CT scans and angiography. Its function is to provide the necessary visual clarity for accurate diagnosis.

---

Q: What are the general guidelines for using Iomeron 350 in patients with a history of asthma or allergies?

A: Official regulatory documents indicate that extra caution is advised when Iomeron 350 is administered to patients who have a history of asthma or general allergies. This is because these individuals have a higher reported incidence of adverse reactions compared to the general population. Use of the drug may be limited to situations where the diagnostic benefit is considered essential.

---

Q: How does having diabetes affect the safety profile when using Iomeron 350?

A: According to official product information, individuals with diabetes mellitus may have a higher risk of temporary impaired renal function (kidney issues) after receiving the contrast agent. For this reason, regulatory information emphasizes the importance of adequate hydration for patients with this condition. This is separate from the necessary precautions taken regarding the interaction with the diabetes medicine Metformin.

---

Q: What conditions related to the blood, such as multiple myeloma, are noted as contraindications?

A: Regulatory documents state that the use of contrast media, including Iomeron 350, should generally be avoided in patients with blood conditions such as multiple myeloma or Waldenstroem's paraproteinemia. This restriction is due to specific risks associated with plasma protein abnormalities in these individuals.

---

Q: What is the guidance regarding Iomeron 350 and possible effects on liver function?

A: Official documents address use in patients with serious hepatic impairment (severe liver problems). In such cases, administration of Iomeron 350 is typically restricted or avoided unless the diagnostic procedure is deemed essential. This is a precaution, as administration may potentially aggravate existing symptoms related to liver function.

---

Q: What are the high-level research themes regarding the overall safety of Iomeron 350?

A: Studies and official information on Iomeron 350 have primarily focused on its diagnostic efficacy compared to other non-ionic contrast agents in its class. Research themes also include monitoring its tolerability (how well the drug is handled by the body) and the continued surveillance of its overall safety profile in different patient groups.

---

Q: How long do expected side effects like a feeling of warmth or nausea typically last?

A: Official sources indicate that common side effects, such as a feeling of warmth or nausea, are usually mild to moderate and transient in nature. This means they are typically of short duration and many common reactions are generally expected to resolve spontaneously without requiring specific intervention.

---

Q: Is it normal to have a slight metallic or unusual taste after receiving the contrast agent?

A: A temporary change in taste, medically termed dysgeusia, is a reported adverse effect of Iomeron 350. According to regulatory documents, this symptom is typically classified as uncommon or of unknown frequency. While it can occur, it is not listed among the most frequent (common) side effects.

---

Q: How is Iomeron 350 removed or eliminated from the patient's body?

A: Official pharmacokinetic data states that Iomeron 350 is primarily eliminated from the body unchanged and is cleared almost exclusively through the kidneys (renal excretion). It is not metabolized by the body.

---

Q: What is the typical period of patient monitoring after Iomeron 350 is administered?

A: Official product information describes that a patient typically remains under observation for at least 30 minutes following the administration of the contrast agent. This timeframe is described because the majority of serious adverse incidents, should they occur, tend to manifest within the first half-hour.

---

Q: Is there a chance Iomeron 350 could cause temporary vision changes?

A: Yes, visual problems are reported adverse effects, though they are classified as uncommon or of unknown frequency in regulatory documents. These can include blurred vision or, in rare cases, temporary (transient) blindness.

---

Q: Are there specific conditions where using Iomeron 350 is contraindicated for procedures involving the female genitalia?

A: According to official product information, Iomeron 350 is contraindicated (should not be used) for procedures involving the female genital organs if pregnancy is suspected or confirmed. It is also contraindicated if the patient has acute inflammatory processes in the genital area.

How to Store and Dispose of Iomeron 350?

Iomeron 350 (iomeprol injection) must be stored according to official regulatory specifications to maintain its stability and efficacy.

Storage Requirements

Condition	Requirement
Temperature	Store below 30°C
Protection	Protect from light and keep in the original container
Child Safety	Keep out of the sight and reach of children

For multi-dose containers, the rubber stopper should never be pierced more than once. Any unused product must be discarded 10 hours after the stopper is first pierced. The unopened solution typically has a shelf-life of five years. Do not use the solution if it is discolored or contains particulate matter.

Disposal Instructions

All residue and waste materials, including solutions not used in one examination session, must be disposed of in accordance with local requirements for pharmaceutical waste.